losartan has been researched along with Renal Insufficiency, Chronic in 60 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 9.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 9.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 9.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| " Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria." | 9.16 | Losartan and enalapril are comparable in reducing proteinuria in children. ( Gleim, GW; Lam, C; Massaad, R; Santoro, EP; Shahinfar, S; Sisk, CM; Webb, NJ; Wells, TG, 2012) |
| "Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats." | 8.12 | Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 5.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 5.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 5.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "Baseline estimated GFR (eGFR) and change in eGFR during follow-up were examined in relation to average on-treatment SBP in 8778 hypertensive patients with ECG left ventricular hypertrophy (LVH) randomly assigned to losartan- or atenolol-based treatment." | 5.22 | Impact of achieved systolic blood pressure on renal function in hypertensive patients. ( Devereux, RB; Kjeldsen, SE; Okin, PM, 2016) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 5.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "To evaluate the clinical efficacy of syndrome differentiation-based treatment with traditional Chinese medicine (TCM) versus losartan therapy in addition to basic treatment for management of proteinuria in patients with chronic kidney disease." | 5.17 | [Syndrome differentiation-based treatment with traditional Chinese medicine for proteinuria in patients with chronic kidney disease: a randomized multicenter trial]. ( Bi, Y; He, L; Mi, X; Peng, W; Wang, D; Wang, Y; Wu, T; Xie, T; Yuan, M, 2013) |
| " Here we assessed an open-label extension of a previous 3-month blinded trial, in which the efficacy and tolerability of losartan was compared to placebo or amlodipine in 306 normotensive and hypertensive children with proteinuria." | 5.16 | Losartan and enalapril are comparable in reducing proteinuria in children. ( Gleim, GW; Lam, C; Massaad, R; Santoro, EP; Shahinfar, S; Sisk, CM; Webb, NJ; Wells, TG, 2012) |
| "Enalapril has similar effects to losartan on systemic blood pressure, renal function and serum UA in patients with CKD, but carries a higher risk of dry cough." | 4.89 | Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2013) |
| " THC was administered via daily oral gavage with the lipid carrier polyenylphosphatidylcholine (PPC) as add-on therapy to losartan (angiotensin receptor blocker) to examine effects on kidney oxidative stress and fibrosis." | 4.31 | Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. ( Khazaali, M; Khazaeli, M; Lau, WL; Nunes, ACF; Prudente, J; Singh, B; Vaziri, ND; Zhao, Y, 2023) |
| "Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats." | 4.12 | Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| " Five patients showed clear adverse reactions, with abdominal or gastrointestinal discomfort." | 3.01 | [Efficacy, safety, and mechanism of Huangkui Capsules in treating chronic kidney disease: Meta-analysis and integrative bioinformatics]. ( Liu, Y; Lyu, J; Wang, FP; Xie, YM; Zhang, L, 2023) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| " The incidence of adverse reactions was not different among the 3 groups (P>0." | 2.79 | Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial. ( Chang, M; Chen, X; Ding, XQ; Fu, P; Guan, GJ; Hao, L; He, LQ; He, YN; Hu, Z; Li, P; Lin, HL; Lin, S; Liu, ZS; Mei, CL; Miao, LN; Wang, JQ; Wang, L; Wang, R; Wu, XF; Xie, RJ; Xing, CY; Yin, AP; Yuan, FH; Zhang, AP; Zhang, L; Zhang, M; Zhao, JY; Zhou, CH, 2014) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| " Patients received open-label treatment with a conventional dosage of benazepril (10 mg/d), individual uptitration of benazepril (median 20 mg/d; range 10 to 40), a conventional dosage of losartan (50 mg/d), or individual uptitration of losartan (median 100 mg/d; range 50 to 200)." | 2.73 | Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. ( Chen, PY; Guo, ZJ; Hou, FF; Jiang, JP; Liang, M; Xie, D; Zhang, WR; Zhang, X, 2007) |
| "Gout is increasing worldwide." | 2.49 | Hypertension, its treatment, hyperuricaemia and gout. ( Gibson, TJ, 2013) |
| "Idiopathic membranous nephropathy is the main cause of chronic kidney disease (CKD)." | 1.72 | Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy. ( Li, J; Lin, Y; Liu, H; Lv, X; Ma, G; Shao, X; Wang, J; Yu, P; Zhang, L; Zhou, S, 2022) |
| " The new model is useful for estimating the risk of drug interaction in clinical practice when AST-120 is used in combination with other drugs." | 1.43 | Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. ( Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S, 2016) |
| " Both single treatments significantly improved systemic and kidney antioxidant defense, bioavailability of renal nitric oxide, reduced kMMP-1 protein expression and renal injury, thus retarded CKD progression." | 1.43 | Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy. ( Grujic-Milanovic, J; Ivanov, M; Jovovic, D; Karanovic, D; Markovic-Lipkovski, J; Mihailovic-Stanojevic, N; Miloradovic, Z; Vajic, UJ; Zivotic, M, 2016) |
| "Enalapril was found to be more reno-protective compared to losartan." | 1.40 | COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL. ( Mugendi, GA; Mwangi, M; Ndwiga, S; Nyamu, DG; Nyamweya, NN; Okalebo, FA, 2014) |
| "Insulin resistance was more remarkable in the N group compared with the control and NA groups." | 1.39 | Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. ( Chang, CF; Chao, YW; Chen, JY; Huang, SW; Jian, DY; Juan, CC; Ting, CH, 2013) |
| "Losartan acts as an immunomodulator that prevents the development of CD14+CD16+ pro-inflammatory monocytes in HD patients." | 1.38 | Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients. ( Aljama, P; Alvarez-Lara, MA; Carracedo, J; Martin-Malo, A; Merino, A; Ramirez, R, 2012) |
| "Losartan treatment increased urine and tissue ACE activity and tissue levels of angiotensins, mainly angiotensin (1-7), and improved renal and histopathologic parameters." | 1.38 | Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats. ( Aragão, DS; Arita, DY; Arita, LS; Casarini, DE; Colucci, JA; Cunha, TS; Nogueira, MD; Perez, JD; Ronchi, FA; Teixeira, Vde P, 2012) |
| " Doses were adjusted to equipotent inhibition of the renin-angiotensin system, determined via a dose-response quantifying plasma and renal renin expression." | 1.38 | AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease. ( Baucke, J; Danser, AH; Divac, N; Fraune, C; Frenay, AR; Garrelds, IM; Hölzel, A; Jankowski, V; Krebs, C; Lange, S; Nguyen, G; Schwedhelm, E; Stahl, R; Streichert, T; van Goor, H; Velden, J; Wenzel, UO, 2012) |
| "Losartan was administered at a dose of 50 mg/d." | 1.33 | Effect of losartan on slowing progression of chronic allograft nephropathy. ( Fan, MQ; Fang, ZQ; Feng, JY; Huang, CB; Wang, PX; Xiao, Y; Zhang, YP, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (11.67) | 29.6817 |
| 2010's | 39 (65.00) | 24.3611 |
| 2020's | 14 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kovács, ZZA | 1 |
| Szűcs, G | 1 |
| Freiwan, M | 1 |
| Kovács, MG | 1 |
| Márványkövi, FM | 1 |
| Dinh, H | 1 |
| Siska, A | 1 |
| Farkas, K | 1 |
| Kovács, F | 1 |
| Kriston, A | 1 |
| Horváth, P | 1 |
| Kővári, B | 1 |
| Cserni, BG | 1 |
| Cserni, G | 1 |
| Földesi, I | 1 |
| Csont, T | 1 |
| Sárközy, M | 1 |
| van Thiel, BS | 1 |
| van der Linden, J | 1 |
| Ridwan, Y | 1 |
| Garrelds, IM | 3 |
| Vermeij, M | 1 |
| Clahsen-van Groningen, MC | 2 |
| Qadri, F | 1 |
| Alenina, N | 1 |
| Bader, M | 1 |
| Roks, AJM | 1 |
| Danser, AHJ | 2 |
| Essers, J | 1 |
| van der Pluijm, I | 1 |
| Mårup, FH | 1 |
| Peters, CD | 1 |
| Christensen, JH | 1 |
| Birn, H | 1 |
| Askaripour, M | 1 |
| Najafipour, H | 1 |
| Saberi, S | 1 |
| Jafari, E | 1 |
| Rajabi, S | 1 |
| Yoo, TH | 2 |
| Hong, SJ | 1 |
| Kim, S | 1 |
| Shin, S | 1 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Han, SY | 1 |
| Lee, S | 1 |
| Won, JC | 1 |
| Kang, YS | 1 |
| Park, J | 1 |
| Han, BG | 1 |
| Na, KR | 1 |
| Hur, KY | 1 |
| Kim, YJ | 2 |
| Park, S | 2 |
| Lv, X | 1 |
| Wang, J | 1 |
| Zhang, L | 3 |
| Shao, X | 1 |
| Lin, Y | 1 |
| Liu, H | 1 |
| Ma, G | 1 |
| Li, J | 2 |
| Zhou, S | 1 |
| Yu, P | 1 |
| Khazaeli, M | 1 |
| Nunes, ACF | 1 |
| Zhao, Y | 1 |
| Khazaali, M | 1 |
| Prudente, J | 1 |
| Vaziri, ND | 1 |
| Singh, B | 1 |
| Lau, WL | 1 |
| Liu, B | 1 |
| Jie, X | 1 |
| Deng, J | 1 |
| Zhang, S | 1 |
| Lu, F | 1 |
| Liu, X | 1 |
| Zhang, D | 1 |
| Santos, ISR | 1 |
| Martin-Pastor, M | 1 |
| Tavares Júnior, AG | 1 |
| Queiroz, KA | 1 |
| da Silva Sólon, LG | 1 |
| Sousa, FFO | 1 |
| Cooper, TE | 1 |
| Teng, C | 1 |
| Tunnicliffe, DJ | 1 |
| Cashmore, BA | 1 |
| Strippoli, GF | 1 |
| Wang, FP | 1 |
| Lyu, J | 1 |
| Liu, Y | 1 |
| Xie, YM | 1 |
| Bovée, DM | 1 |
| Ren, L | 1 |
| Uijl, E | 1 |
| van Veghel, R | 1 |
| Domenig, O | 1 |
| Poglitsch, M | 1 |
| Zlatev, I | 1 |
| Kim, JB | 1 |
| Huang, S | 1 |
| Melton, L | 1 |
| Lu, X | 1 |
| Hoorn, EJ | 1 |
| Foster, D | 1 |
| Hashimoto, T | 1 |
| Shibata, K | 1 |
| Honda, K | 1 |
| Nobe, K | 1 |
| Ragab, TIM | 1 |
| Ali, NA | 1 |
| El Gendy, ANG | 1 |
| Mohamed, SH | 1 |
| Shalby, AB | 1 |
| Farrag, AH | 1 |
| Shalaby, ASG | 1 |
| Fujihara, CK | 3 |
| Kowala, MC | 1 |
| Breyer, MD | 1 |
| Sena, CR | 1 |
| Rodrigues, MV | 1 |
| Arias, SCA | 1 |
| Fanelli, C | 3 |
| Malheiros, DM | 3 |
| Jadhav, PK | 1 |
| Montrose-Rafizadeh, C | 1 |
| Krieger, JE | 1 |
| Zatz, R | 3 |
| García Trejo, EMÁ | 1 |
| Arellano Buendía, AS | 1 |
| Sánchez Reyes, O | 1 |
| García Arroyo, FE | 1 |
| Arguello García, R | 1 |
| Loredo Mendoza, ML | 1 |
| Tapia, E | 1 |
| Sánchez Lozada, LG | 1 |
| Osorio Alonso, H | 1 |
| Kim, JY | 1 |
| Son, JW | 1 |
| Ryu, DR | 1 |
| Chin, HJ | 1 |
| Montes-Rivera, JO | 1 |
| Tamay-Cach, F | 1 |
| Quintana-Pérez, JC | 1 |
| Guevara-Salazar, JA | 1 |
| Trujillo-Ferrara, JG | 1 |
| Del Valle-Mondragón, L | 1 |
| Arellano-Mendoza, MG | 1 |
| Okin, PM | 1 |
| Kjeldsen, SE | 1 |
| Devereux, RB | 1 |
| Alvarez, M | 1 |
| Ardiles, L | 1 |
| Arias, SC | 1 |
| Valente, CP | 1 |
| Machado, FG | 2 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Jian, DY | 1 |
| Chao, YW | 1 |
| Ting, CH | 1 |
| Huang, SW | 1 |
| Chang, CF | 1 |
| Juan, CC | 1 |
| Chen, JY | 1 |
| Wang, D | 1 |
| Wu, T | 1 |
| Xie, T | 1 |
| Peng, W | 2 |
| Wang, Y | 2 |
| Yuan, M | 1 |
| Mi, X | 1 |
| Bi, Y | 1 |
| He, L | 1 |
| Palkovits, M | 1 |
| Šebeková, K | 1 |
| Klenovics, KS | 1 |
| Kebis, A | 1 |
| Fazeli, G | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Xu, C | 1 |
| Ding, W | 1 |
| Zhang, M | 2 |
| Gu, Y | 1 |
| Li, P | 1 |
| Xing, CY | 1 |
| Zhao, JY | 1 |
| He, YN | 1 |
| Wang, JQ | 1 |
| Wu, XF | 1 |
| Liu, ZS | 1 |
| Zhang, AP | 1 |
| Lin, HL | 1 |
| Ding, XQ | 2 |
| Yin, AP | 1 |
| Yuan, FH | 1 |
| Fu, P | 1 |
| Hao, L | 1 |
| Miao, LN | 1 |
| Xie, RJ | 1 |
| Wang, R | 1 |
| Zhou, CH | 1 |
| Guan, GJ | 1 |
| Hu, Z | 1 |
| Lin, S | 1 |
| Chang, M | 1 |
| He, LQ | 3 |
| Mei, CL | 1 |
| Wang, L | 1 |
| Chen, X | 1 |
| Woo, KT | 1 |
| Choong, HL | 1 |
| Wong, KS | 1 |
| Tan, HK | 1 |
| Foo, M | 1 |
| Fook-Chong, S | 1 |
| Lee, EJ | 1 |
| Anantharaman, V | 1 |
| Lee, GS | 1 |
| Chan, CM | 1 |
| Fujisaki, K | 1 |
| Tsuruya, K | 1 |
| Nakano, T | 1 |
| Taniguchi, M | 1 |
| Higashi, H | 1 |
| Katafuchi, R | 1 |
| Kanai, H | 1 |
| Nakayama, M | 1 |
| Hirakata, H | 1 |
| Kitazono, T | 1 |
| Hayashi, M | 1 |
| Uchida, S | 2 |
| Kawamura, T | 1 |
| Kuwahara, M | 1 |
| Nangaku, M | 1 |
| Iino, Y | 1 |
| Yao, Y | 1 |
| Hildreth, CM | 1 |
| Farnham, MM | 1 |
| Saha, M | 1 |
| Sun, QJ | 1 |
| Pilowsky, PM | 1 |
| Phillips, JK | 1 |
| Wu, F | 1 |
| Zhang, PQ | 1 |
| Wang, XQ | 1 |
| Nie, LF | 1 |
| Fu, XJ | 1 |
| Bi, YP | 1 |
| Mi, XH | 1 |
| Gong, XZ | 1 |
| Zhou, LF | 1 |
| Wang, Q | 1 |
| Tang, XC | 1 |
| Qian, YR | 1 |
| Wang, YR | 1 |
| Lu, L | 1 |
| Zhou, JJ | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 1 |
| Gansevoort, RT | 1 |
| Mo, L | 1 |
| Xiao, X | 1 |
| Song, S | 1 |
| Miao, H | 1 |
| Liu, S | 1 |
| Guo, D | 1 |
| Li, X | 1 |
| Bu, C | 1 |
| Hou, L | 1 |
| Yang, X | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Mehrotra, P | 1 |
| Patel, JB | 1 |
| Ivancic, CM | 1 |
| Collett, JA | 1 |
| Basile, DP | 1 |
| Rodríguez-Romo, R | 1 |
| Benítez, K | 1 |
| Barrera-Chimal, J | 1 |
| Pérez-Villalva, R | 1 |
| Gómez, A | 1 |
| Aguilar-León, D | 1 |
| Rangel-Santiago, JF | 1 |
| Huerta, S | 1 |
| Gamba, G | 1 |
| Uribe, N | 1 |
| Bobadilla, NA | 1 |
| Hsing, SC | 1 |
| Lu, KC | 1 |
| Sun, CA | 1 |
| Chien, WC | 1 |
| Chung, CH | 1 |
| Kao, SY | 1 |
| Mugendi, GA | 1 |
| Nyamu, DG | 1 |
| Okalebo, FA | 1 |
| Nyamweya, NN | 1 |
| Ndwiga, S | 1 |
| Mwangi, M | 1 |
| Anan, HH | 1 |
| Zidan, RA | 1 |
| Shaheen, MA | 1 |
| Abd-El Fattah, EA | 1 |
| Koya, Y | 1 |
| Machi, Y | 1 |
| Shobu, Y | 1 |
| Namiki, N | 1 |
| Kotegawa, T | 1 |
| Karanovic, D | 1 |
| Grujic-Milanovic, J | 1 |
| Miloradovic, Z | 1 |
| Ivanov, M | 1 |
| Jovovic, D | 1 |
| Vajic, UJ | 1 |
| Zivotic, M | 1 |
| Markovic-Lipkovski, J | 1 |
| Mihailovic-Stanojevic, N | 1 |
| Guo, LL | 1 |
| Pan, Y | 1 |
| Jin, HM | 1 |
| Kondo, S | 1 |
| Urushihara, M | 1 |
| Kagami, S | 1 |
| Merino, A | 1 |
| Alvarez-Lara, MA | 1 |
| Ramirez, R | 1 |
| Carracedo, J | 1 |
| Martin-Malo, A | 1 |
| Aljama, P | 1 |
| Arita, DY | 1 |
| Cunha, TS | 1 |
| Perez, JD | 1 |
| Colucci, JA | 1 |
| Ronchi, FA | 1 |
| Nogueira, MD | 1 |
| Arita, LS | 1 |
| Aragão, DS | 1 |
| Teixeira, Vde P | 1 |
| Casarini, DE | 1 |
| Vaněčková, I | 1 |
| Kujal, P | 1 |
| Husková, Z | 1 |
| Vaňourková, Z | 1 |
| Vernerová, Z | 1 |
| Certíková Chábová, V | 1 |
| Skaroupková, P | 1 |
| Kramer, HJ | 1 |
| Tesař, V | 1 |
| Červenka, L | 1 |
| Webb, NJ | 1 |
| Shahinfar, S | 1 |
| Wells, TG | 1 |
| Massaad, R | 1 |
| Gleim, GW | 1 |
| Santoro, EP | 1 |
| Sisk, CM | 1 |
| Lam, C | 1 |
| Fraune, C | 1 |
| Lange, S | 1 |
| Krebs, C | 1 |
| Hölzel, A | 1 |
| Baucke, J | 1 |
| Divac, N | 1 |
| Schwedhelm, E | 1 |
| Streichert, T | 1 |
| Velden, J | 1 |
| Danser, AH | 1 |
| Frenay, AR | 1 |
| van Goor, H | 1 |
| Jankowski, V | 1 |
| Stahl, R | 1 |
| Nguyen, G | 1 |
| Wenzel, UO | 1 |
| Shen, PC | 1 |
| Yang, XJ | 1 |
| Cao, HX | 1 |
| Suzuki, H | 2 |
| Shimada, Y | 1 |
| Fujiwara, K | 1 |
| Gibson, TJ | 1 |
| Wang, PX | 1 |
| Fan, MQ | 1 |
| Huang, CB | 1 |
| Feng, JY | 1 |
| Xiao, Y | 1 |
| Fang, ZQ | 1 |
| Zhang, YP | 1 |
| Deng, W | 1 |
| Ding, HG | 1 |
| Chen, J | 1 |
| Yamamoto, T | 1 |
| Nakagawa, T | 1 |
| Ohashi, N | 1 |
| Fukasawa, H | 1 |
| Fujigaki, Y | 1 |
| Kato, A | 1 |
| Nakamura, Y | 1 |
| Suzuki, F | 1 |
| Hishida, A | 1 |
| Hou, FF | 1 |
| Xie, D | 1 |
| Zhang, X | 1 |
| Chen, PY | 1 |
| Zhang, WR | 1 |
| Liang, M | 1 |
| Guo, ZJ | 1 |
| Jiang, JP | 1 |
| Chiang, WC | 1 |
| Lin, SL | 1 |
| Chen, YM | 1 |
| Wu, KD | 1 |
| Tsai, TJ | 1 |
| Poppi, EP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02620306] | Phase 3 | 351 participants (Actual) | Interventional | 2016-02-11 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial[NCT02231125] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease：a Multicentre Open Study[NCT02231138] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension[NCT00568178] | Phase 3 | 306 participants (Actual) | Interventional | 2007-06-01 | Completed | ||
| Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy[NCT01300273] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-02-28 | Active, not recruiting | ||
| Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers[NCT00857844] | 207 participants (Actual) | Observational | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -3.8 |
| Amlodipine-Hypertensive Participants | 0.8 |
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -5.5 |
| Amlodipine-Hypertensive Participants | -0.1 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately twelve weeks of treatment.~Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period." (NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan | -35.80 |
| Amlodipine/Placebo | 1.37 |
"The outcome measure of glomerular filtration rate was based on mL/min/1.73m^2, as determined by the Schwartz formula:~GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL)~GFR values were compared to the baseline GFR measure.~[Note: For male participants, ages 13 to 17 years, 0.70 was used as~the multiplier in place of 0.55]~Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Change in GFR mL/min1.73m^2 (Least Squares Mean) |
|---|---|
| Losartan Open Label Extension | 3.3 |
| Enalapril Open Label Extension | 7.0 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately three years of treatment.~*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan Open Label Extension | -30.01 |
| Enalapril Open Label Extension | -40.45 |
5 reviews available for losartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2023 |
[Efficacy, safety, and mechanism of Huangkui Capsules in treating chronic kidney disease: Meta-analysis and integrative bioinformatics].
Topics: Capsules; Drugs, Chinese Herbal; Humans; Inflammation; Losartan; Renal Insufficiency, Chronic | 2023 |
Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biom | 2013 |
[Progress of pediatric nephrology].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antibodies, Monoclonal, Murine-Derived; Bio | 2011 |
Hypertension, its treatment, hyperuricaemia and gout.
Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemi | 2013 |
18 trials available for losartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Hum | 2022 |
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2022 |
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials, Phase III | 2017 |
Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Female; Glomerular Fil | 2016 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
[Syndrome differentiation-based treatment with traditional Chinese medicine for proteinuria in patients with chronic kidney disease: a randomized multicenter trial].
Topics: Adult; Aged; Drugs, Chinese Herbal; Female; Humans; Losartan; Male; Medicine, Chinese Traditional; M | 2013 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Aliskiren and losartan trial in non-diabetic chronic kidney disease.
Topics: Amides; Blood Pressure; Comorbidity; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationsh | 2014 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular | 2014 |
Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2015 |
[Multi-center randomized control study on the effects of syndrome differentiated traditional Chinese medicine therapy on CKD 1-2 with chronic nephritis proteinuria].
Topics: Cell Differentiation; Drugs, Chinese Herbal; Glomerular Filtration Rate; Glomerulonephritis; Humans; | 2015 |
[Effect of Chuanhuang No. 1 recipe on renal function and micro-inflammation in phase 3 chronic kidney disease patients].
Topics: Adult; Blood Urea Nitrogen; C-Reactive Protein; Drugs, Chinese Herbal; Female; Humans; Inflammation; | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Losartan and enalapril are comparable in reducing proteinuria in children.
Topics: Adolescent; Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2012 |
Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Blood Pressure; China; Female; Glomerular Fil | 2012 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensinogen; Antihypertensive Agents | 2007 |
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2007 |
37 other studies available for losartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Antihypertensive Agents; Cardiomyopathie | 2021 |
In Vivo Renin Activity Imaging in the Kidney of Progeroid
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; DNA | 2021 |
Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions.
Topics: Aged; Animals; Antioxidants; Female; Fibrosis; Humans; Inflammation; Isoflavones; Kidney; Losartan; | 2022 |
Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy.
Topics: Animals; Autophagy; Canagliflozin; Glomerulonephritis, Membranous; Losartan; Podocytes; Rats; Renal | 2022 |
Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury.
Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
Bupi Yishen formula may prevent kidney fibrosis by modulating fatty acid metabolism in renal tubules.
Topics: Animals; Fatty Acids; Fibrosis; Humans; Kidney; Losartan; Rats; Renal Insufficiency, Chronic | 2023 |
Metabolomic Profile and Its Correlation with the Plasmatic Levels of Losartan, EXP3174 and Blood Pressure Control in Hypertensive and Chronic Kidney Disease Patients.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Losartan; Renal Insufficiency, Chroni | 2023 |
Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Arterial Pressure; Captopril; Dis | 2021 |
Acetic acid treatment causes renal inflammation and chronic kidney disease in mice.
Topics: Acetic Acid; Animals; Creatine; Disease Models, Animal; Gene Expression; Interleukin-1beta; Kidney; | 2021 |
Renoprotective and therapeutic effects of newly water, ethanol, and butanol ginseng fractions in hypertensive and chronic kidney disease with L-NAME.
Topics: Animals; Butanols; Disease Models, Animal; Ethanol; Female; Gas Chromatography-Mass Spectrometry; Ge | 2021 |
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Losartan; Mineralocorticoid Receptor | 2017 |
The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan.
Topics: Acetylglucosaminidase; Animals; Antihypertensive Agents; Antioxidants; Creatinine; Disulfides; Kelch | 2017 |
Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease.
Topics: Acetophenones; Adjuvants, Pharmaceutic; Animals; Antihypertensive Agents; Antioxidants; Blood Pressu | 2018 |
[Prescription of renin-angiotensin-aldosterone system blockers in patients with stage 3 chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; D | 2019 |
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats.
Topics: Adipokines; Adiposity; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ce | 2013 |
Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Brain; Central Nervous Sy | 2013 |
Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease.
Topics: Angiopoietins; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Dise | 2013 |
The effect of losartan on differential reflex control of sympathetic nerve activity in chronic kidney disease.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Pathways; Baroreflex; Ki | 2015 |
Protective effect of Huang Gan formula in 5/6 nephrectomized rats by depressing the Wnt/β-catenin signaling pathway.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Kidney Fun | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultur | 2015 |
AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Drug Evaluation, Preclinical; | 2016 |
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2015 |
COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL.
Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Diabetic Nephropathies; Enalapril; Female; Humans; | 2014 |
Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Disease Models, Animal; Disease Progression | 2016 |
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Topics: Administration, Oral; Adsorption; Aluminum Hydroxide; Amlodipine; Aspirin; Carbon; Drug Interactions | 2016 |
Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy.
Topics: Animals; Antihypertensive Agents; Antioxidants; Cyclic N-Oxides; Drug Therapy, Combination; Female; | 2016 |
Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients.
Topics: Antihypertensive Agents; Case-Control Studies; Cell Differentiation; Cells, Cultured; Female; Flow C | 2012 |
Overexpression of urinary N-domain ACE in chronic kidney dysfunction in Wistar rats.
Topics: Animals; Disease Models, Animal; Losartan; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Renal I | 2012 |
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasent | 2012 |
AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressur | 2012 |
Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Effect of losartan on slowing progression of chronic allograft nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Creatinine; Disease Progression; F | 2005 |
[Treatment of chronic renal insufficiency with losartan and traditional Chinese drug for invigorating spleen and kidney].
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Kidney; Losartan; Medicine, Chinese Traditional; Re | 2006 |
Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chemokine CCL2; Cytokines; Female; Follow-Up St | 2008 |
AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Female; Hypertension, Rena | 2008 |